TACE treatment in hepatocellular carcinoma: What should we do now?

Journal of Hepatology

Volumn 57, Issue 1, 2012, Pages 221-222

  Farinati, Fabio ^a   Giacomin, Anna ^a   Vanin, Veronica ^a   Giannini, Edoardo ^b   Trevisani, Franco ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; TAMOXIFEN;

CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; HUMAN; LETTER; LIVER CELL CARCINOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84862647838     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.12.022     Document Type: Letter

References (10)

1. Forner A, Llovet JM, Bruix J. Chemoembolization for intermediate HCC: is there proof of survival benefit? J Hepatol 2012;56:984-986.
2. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo) embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011:CD004787.
3. Eccles M, Rousseau N, Freemantle N. Updating evidence-based clinical guidelines. J Health Serv Res Policy 2002;7:98-103.
4. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739.
5. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization: a multicenter randomized trial. Hepatology 2002;35:1164-1171.
6. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442.
7. Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224:47-54.
8. Doffoël M, Bonnetain F, Bouché O, Vetter D, Abergel A, Fratté S, et al. Fédération Francophone de Cancérologie Digestive. Multicentre randomised phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédé ration Francophone de Cancérologie Digestive 9402). Eur J Cancer 2008;44:528-538.
9. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagège H, Dao T, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998;29:129-134.
10. Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990;11:181-184.